.. a little under 60% of these encounters resulted in hospitalization and of these, about 13% required intensive care..eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention..
"we were fully aware of the fact that our twins would be the first babies in the world to receive this treatment in utero," corinna said..
.,maxcontain(158,100),quality(90))
., an emerita professor in the department of food science & technology at uc davis..
.